Atopic Dermatitis (Eczema) Study

Do you have moderate to severe atopic dermatitis (for at least one year)?

A clinical trial designed to evaluate if the trial drug, tralokinumab, can affect the body’s immune responses to vaccines for adult patients with moderate sever atopic dermatitis is currently being conducted.

All subjects will receive injections of trial medication or placebo every other week for up to 14 weeks. For all trial participants, the trial will include up to 12 visits to the trial clinic.

Atopic dermatitis (AD) is a chronic inflammatory skin disease. In its severe form, AD is characterised by widespread skin lesions, itch, as well as increased risk of skin infections. AD is associated with a substantial burden that typically includes poor quality of life, sleep disturbance, and reductions in work productivity.

There is no cost to participate in this clinical study and reasonable travel expenses will be reimbursed.

If you have atopic dermatitis and are interested in participating in a clinical trial, please fill out the form below or call us at (423) 698-4584.

Please provide the following information so that we can contact you regarding enrolling in our current and upcoming studies. Provide only information you feel comfortable transmitting to our secure website via the internet. Your information will NOT be shared with anyone else and will only be used to contact you regarding potential involvement in our studies and for sending you study related newsletters and mailings.